Insmed Incorporated (INSM) Earnings Call Transcript & Summary

October 29, 2026

NASDAQ US Health Care Biotechnology earnings 62 min

Earnings Call Speaker Segments

Will Lewis

executive
#1

Good morning, everyone. The updates we're sharing today are meant to bring three big-picture ideas to life. First, Insmed has become a diversified biotech company that we think is capable of producing meaningful revenue and earnings, with considerable growth ahead over the coming 10 years and well past that. Beyond surpassing $1 billion in total company revenue year to date, I'm happy to report that BRINSUPRI has already reached blockbuster status, generating over $1 billion in revenue across its first four full quarters of launch. We feel we've barely begun to tap the potential addressable patients who could benefit from this first-ever approved foundational medicine in bronchiectasis. We treated tens of thousands of patients during the first year, yet hundreds of thousands of patients are already diagnosed and waiting, and potentially millions more may benefit. We have truly only started to witness the benefit BRINSUPRI will deliver to patients, and all of this has come while we keep delivering for patients with NTM through ARIKAYCE. Given that performance, we are raising full year 2026 guidance for both products. I take real pride in what we've accomplished, though there is always room for us to improve. My belief remains that the growth road ahead for our medicines is very substantial. Looking forward, we've forecast that our three lead respiratory assets will collectively grow at a compound annual growth rate above 20% across the next 10 plus years; on that basis, we expect those three lead respiratory assets to surpass $14 billion in estimated peak sales combined, with room for potential upside. BRINSUPRI's peak sales estimate of more than $7 billion excludes the COPD and asthma comorbid patient populations, which we estimate add low single-digit millions of additional patients. We believe the future impact of BRINSUPRI on these additional patients — who are on max dose treatments for their conditions yet still suffer damage from exacerbations — could be significant. The revenue that could follow from success in treating these patients might represent potentially as much as, or even more than, the current $7 billion peak sales estimate; in a moment, I'll discuss the initiatives we're deploying to seize this important opportunity. TPIP is likewise expected to be a massive product, potentially reaching the market by the end of this decade, with a peak sales estimate of more than $6 billion across four separate indications. So far, TPIP has set itself apart within the prostanoid class through superior improvement in six-minute walk distance and PVR reduction, among other efficacy measures, plus better safety and convenience thanks to its clearly differentiated profile. We believe TPIP, a once-daily inhaled treprostinil prodrug, could unlock clinical, safety, and convenience benefits not previously known, through a validated mechanism of action. Let me be very direct about this: we stay completely ready for whatever challenges arise from companies attempting to block patients from potentially getting this innovative therapy. And last, we think ARIKAYCE — with a possible label expansion next year — could reach peak sales above $1 billion, with U.S. launch prep and Japan preparations both well advanced, assuming approvals come through in both territories. In our view, a diversified respiratory portfolio where each asset we believe can become a blockbuster will let us deliver some of the best revenue growth and, in time, earnings growth, and will put Insmed at or near the leading edge of commercial-stage biopharma companies for the foreseeable future. The second point is that Insmed keeps showing operational excellence. Our gauge of operational excellence is how well we produce strong revenue while expanding the commercial, clinical, and technical capabilities built for our future. Right now, that operational excellence shows in the ongoing progress of our four phase III TPIP trials in PHILD, PAH, PPF, and IPF. It will keep showing through the expected start of multiple phase II programs across the coming several years. Assuming positive data from the phase I healthy volunteer study of INS1033, we anticipate launching a phase II study in rheumatoid arthritis in 2027, then ulcerative colitis and COPD. Also in 2027, we intend to start a phase II study of INS1148 in IPF, with plans to assess it in PPF and other inflammatory and fibrotic diseases after that. The third point is that our research engine keeps pushing forward therapies we believe can be first or best in class. In 2027, we expect to report data from our phase I gene therapy programs in DMD and ALS. We are also restating our guidance to file one to two INDs each year through the end of the decade. Although many more programs are under evaluation, we presently see a clear path to nine research programs spanning our four research centers, and we believe all of them could be first- or best-in-class medicines. Those programs could enter the clinic between now and 2029, and we think several might qualify for accelerated approval. Outside our internal pipeline, we keep an active business development effort hunting for medicines like BRINSUPRI. Such assets are very hard to find, but we believe they exist. The takeaway: combining sustained commercial growth, operational excellence, and differentiated scientific innovation could set Insmed apart from its peers and place it at the forefront of high-performing biotechnology companies. Now let's look more closely at BRINSUPRI. BRINSUPRI generated $400.1 million in revenue in the third quarter of 2026; that equals 29% sequential growth compared with the prior quarter. Looking at slide 7, it's clear that BRINSUPRI's revenue keeps outpacing other powerful respiratory launches — blockbusters such as DUPIXENT, TEZSPIRE, FASENRA, and WINREVAIR included — when you compare quarterly revenue on a launch-aligned basis. August 12th marked the one-year anniversary of BRINSUPRI's FDA approval and its U.S. launch, and we celebrated that milestone. Now that we have more than a year of commercial launch under our belt, I'm glad to say our performance still excites us when measured against key internal launch benchmarks, and we stay comfortable with the historic direction we've given on metrics such as new patient starts, which we think could expand as we move through 2027. As we said before, having now passed the first full year of launch, we don't intend to keep providing specific updates on each individual launch metric. Our performance makes us extremely happy, and we're seeing particular strength in payer approval rates, reauthorization rates, persistency, and dispenses, along with continuing positive feedback from patients who tell us they feel better on BRINSUPRI. Across the board, we're pleased with where we stand and where we're headed. We stay focused on continually refining our commercial strategy and optimizing how we allocate resources so the launch's potential is maximized. For instance, we keep sharpening our approach to physician engagement, putting top-tier prescribers first where we see the biggest opportunity for greater depth.

Will Lewis

executive
#2

We're also eager to roll out our inaugural branded TV campaign, and it should dovetail with the slate of unbranded campaigns we already run, ideally helping bronchiectasis patients realize that a once-daily oral therapy with approval may suit them. Our analysis shows this kind of commercial push tends to deliver a very strong return on investment, and we're looking forward to kicking it off next month. With BRINSUPRI consistently beating expectations so far, we're lifting our full-year 2026 revenue guidance to a range of $1.35 billion-$1.4 billion, which takes the bottom of our prior range up by $100 million. Now on to Japan. We officially introduced BRINSUPRI 25-milligram tablets there last week. For bronchiectasis patients in Japan, BRINSUPRI stands as the first and only approved medicine. As you'll recall, roughly 150,000 patients in Japan carry a current bronchiectasis diagnosis; in our phase III ASPEN study, Japanese patients showed a considerably larger drop in exacerbations — a 68% reduction in annualized exacerbation rate, versus about 20% in the global study. Beyond that, Japanese patients saw more than double the lung function improvement recorded in the global study, measured through change in FEV1 and FVC. We don't know the biological explanation for this gap, but it is striking and highlights how BRINSUPRI could profoundly change life for Japanese patients living with bronchiectasis. Thanks to this positive clinical effect among Japanese patients, we're also glad to have obtained highly favorable pricing for BRINSUPRI in Japan. We anticipate Japan will be the primary force behind any BRINSUPRI sales outside the U.S. Keep in mind that precedent from other specialty medicines introduced in the U.S., Europe, and Japan indicates that, taken together, markets outside the U.S. generally account for about 10%-15% of global peak sales. We're spurred on by the chance to serve patients in Japan, and we applaud our Japanese colleagues' hard work in hitting this key milestone while still delivering strong ARIKAYCE results over the past several years. Now turning to what we're doing to build real-world evidence for BRINSUPRI. Our medical and clinical teams have been working diligently to assemble a solid body of long-term evidence behind BRINSUPRI; in August, the Bronchiectasis and NTM Association announced we would collaborate on the first in-disease observational study assessing real-world effectiveness of 10 and 25 milligrams of brensocatib. The Brensocatib Effectiveness, Safety, and Tolerability in Bronchiectasis, or BEST-BE study, is built to gauge how often and how frequently pulmonary exacerbations occur in non-cystic fibrosis bronchiectasis patients across a two-year span. Patients' quality-of-life changes, along with how often adverse events arise, will also be followed in the study. Enrollment targets 1,000 adults at 13 U.S. sites, and key secondary measures cover lung function changes, time to next exacerbation, severe exacerbation rate, plus the presence of respiratory pathogens and NTM culture conversion. In our view, the BEST-BE study will reinforce the long-term evidence base for BRINSUPRI in the U.S. And we can also back up what we're seeing through our strategic partnership with EMBARC in Europe. Just to remind everyone, EMBARC is running an open-label, three-year trial of brensocatib at 25 milligrams, enrolling up to 3,000 patients across six countries in Europe. That study is designed to assess whether treating patients with brensocatib over the long term can change how bronchiectasis progresses, and whether starting brensocatib earlier can slow the disease down even more. We're eager to collaborate with the Bronchiectasis and NTM Association and EMBARC to turn real-world evidence into practical strategies that enhance diagnosis and treatment for bronchiectasis patients, while also reinforcing Insmed's leadership in this area; alongside our BRINSUPRI real-world evidence work, a dedicated task force has been focused on pushing forward efforts that boost awareness of comorbid bronchiectasis among COPD and asthma patients and assist physicians in making better treatment choices; we see this comorbid bronchiectasis opportunity within the COPD and asthma populations as one of Insmed's biggest potential value drivers, an underdiagnosed bronchiectasis population that may be several times the size of the roughly 500,000 patients diagnosed in the U.S. today. Should even a single-digit percentage of the roughly 32 million U.S. patients with COPD or asthma turn out to have undiagnosed bronchiectasis, the addressable population for BRINSUPRI could grow to several million patients. Notably, this comorbid opportunity isn't part of BRINSUPRI's current peak sales opportunity of more than $7 billion, which is why I said earlier that this peak sales estimate may have meaningful upside. You've heard us talk before about the work the American Thoracic Society is doing on the diagnosis side, and about our launch of the Suspect BE Celebrity Awareness Campaign. As a reminder, ATS is looking at how physicians spot bronchiectasis in clinical practice, to help shift default diagnostic habits to specifically complement bronchiectasis. The Suspect BE campaign is meant to prompt patients with COPD or asthma who still have symptoms to seek a further diagnosis from a pulmonologist. Today, I'm glad to share more specifics about our wider diagnosis strategy. Our efforts fall into three strategic priorities. First comes generating evidence to establish the prevalence and scale of undiagnosed bronchiectasis among patients with COPD or asthma. Second is forming strategic partnerships to explore ways to transform how bronchiectasis gets detected and diagnosed in the care setting. Third is educating healthcare providers so they better understand and identify bronchiectasis in their patients. Our evidence generation efforts started earlier this year with three leading COPD and asthma centers in the U.S., using retrospective imaging analysis to find previously undiagnosed bronchiectasis and assess approaches for improving detection. We aim to transform the way bronchiectasis gets recognized in clinical practice—by heightening pulmonologists' and radiologists' suspicion of this disease, promoting routine review of high-res CT scans for signs of it, and bolstering hospital protocols so that process is reinforced for patients; our belief is that such efforts can support earlier diagnosis, enhance disease management, and assist patients in making better-informed choices regarding their care. Beyond our work generating evidence, I'm pleased to report that we're at an early stage of building AI-driven diagnostic tools together with strategic partners. The intention is for these tools to plug into software healthcare providers already use, helping spot bronchiectasis within patients' medical records and applying predictive analytics to flag possible bronchiectasis cases alongside other prevalent pulmonary conditions such as lung cancer, COPD, and asthma. To assist physicians in better identifying bronchiectasis patients within their practices, we recently introduced a disease educator program, rolling out an initial group of 16 trained nurses throughout the U.S.; these educators interact directly with pulmonologists in locations where our data show a high concentration of patients with COPD and asthma. Their job is to aid physicians in spotting indicators of underlying bronchiectasis among patients who might have the disease in addition to or rather than their existing COPD or asthma diagnosis. As we assess the program's impact, we foresee an opportunity to extend this approach to more U.S. sites. These represent only a handful of the initiatives we have invested in so far.

Will Lewis

executive
#3

We’re still very enthusiastic about what these efforts will reveal and about the strategies we plan to put in place because of them. Since a lot of these insights come from backward-looking metrics, we expect to share our first results around the middle of next year. Now I’ll move to ARIKAYCE. On the commercial side, ARIKAYCE keeps performing, with $124.4 million in revenue during the third quarter of 2026, reflecting 9% growth year over year compared with the same period a year earlier. After three quarters of solid results, we’re lifting our full-year 2026 ARIKAYCE revenue guidance range to $460 million-$470 million, which raises the bottom end of our prior range by $10 million; on the regulatory side, I’m pleased to say that in September, the FDA granted ARIKAYCE priority review for its supplemental New Drug Application for treating MAC lung disease. The PDUFA target action date is January 28, 2027. Importantly, the FDA said it does not currently intend to hold an advisory committee meeting to discuss this application. Acceptance of this application is a key milestone in our goal to transform the treatment paradigm for patients with MAC lung disease. If full approval is granted, ARIKAYCE could reach patients earlier in the course of their disease, including people who are newly diagnosed or dealing with recurrent infections. In addition, Insmed intends to submit the ENCORE data to Japan’s Pharmaceuticals and Medical Devices Agency during the fourth quarter of 2026 to support a possible label expansion in Japan. If both submissions succeed, we would expect to launch ARIKAYCE with an expanded label in the U.S. and Japan in the first half of 2027. Label expansions covering all patients with MAC lung disease in the U.S. and Japan could grow ARIKAYCE’s addressable market in each region from roughly 15,000 patients today to more than 100,000 patients in the future. That represents a potential total addressable market of more than 200,000 patients across the U.S. and Japan. We look forward to working with the FDA and the PMDA throughout these reviews. Now I’ll turn to TPIP, which I believe will accelerate our growth as we finish out this decade. Earlier this month, Insmed highlighted the global phase III PALM clinical development program at the CHEST 2026 annual meeting. The PALM program, made up of four phase III studies in PHILD, PAH, PPF, and IPF, is one of the broadest active clinical programs in the pulmonary field. If it succeeds, TPIP, a once-daily inhaled treprostinil prodrug, could become the prostanoid of choice for clinicians and patients. Let me give an update on each study. The PALM-ILD study of TPIP in PHILD is still enrolling faster than expected. After its first patient was enrolled in December of last year, the study is now more than 35% enrolled, which reflects the medical community’s enthusiasm for the strength of TPIP’s clinical profile. Given those enrollment patterns, completion of enrollment is anticipated by the first half of 2028 at the latest—under two and a half years from when the study began. Regarding PALM-PAH, we're happy to report that the first patient has now been enrolled, and we believe ongoing enrollment will be helped by the robustness of our TPIP 12-month open label extension data in PAH patients that were presented in July. During the third quarter, the first site was initiated in the PALM-PPF study, which stays on schedule to start enrolling before this year concludes. Finally, PALM-IPF remains on track for initiation in the first half of 2027. Now shifting to the progress across the remainder of our pipeline: as we lay the groundwork for Insmed's long-term success, we keep investing in our earlier-stage programs; this September, INS1033—our second DPP1 candidate—started actively recruiting patients in a phase I healthy volunteer study. We anticipate that data on pharmacokinetic exposure and blood NSP levels will become available next year. Should those results prove positive, we would move into phase II development in rheumatoid arthritis during 2027, then ulcerative colitis and COPD. Also in 2027, we intend to launch a phase II development program for INS1148 in IPF, with plans to assess PPF and other diseases in which blocking the pro-inflammatory and pro-fibrotic responses mediated by stem cell factor 248 might offer benefit. In our gene therapy portfolio, the DMD and ALS programs both remain on track. Our phase I ASCEND study of INS1201 in DMD is now fully enrolled, with 12 pediatric patients across four cohorts, and the data seen so far are encouraging. As a reminder, this study is evaluating two dose levels across two pediatric age groups, with three patients in each cohort. INS1201 is designed for intrathecal delivery, aiming to minimize liver exposure and deliver therapy directly to skeletal muscle and cardiac tissue; we look forward to sharing initial data from multiple cohorts within this program in 2027. Our phase I ARMOR study of INS1202 in ALS has moved into cohort 2 and is actively enrolling patients with both sporadic and SOD1 ALS. Enrollment in the study is expected to reach up to 23 patients, three of whom were already enrolled in cohort 1, all with sporadic ALS and treated at the lowest dose. Cohort 2 is evaluating a middle dose in patients with both sporadic and SOD1 ALS, with five patients planned in each group. If it is determined that patients can safely be dosed higher, we have the option to advance to cohort 3, which would also enroll sporadic and SOD1 patients and evaluate them at the highest dose. We expect to share initial data from this program in 2027. Before I hand the call over to Sara, let me take a moment to thank her publicly for being a critical part of the team that brought us to this position of strength. The results we're reporting today show that Insmed is in as strong a place as it has ever been, and Sara has been instrumental in bringing us to this point — securing capital, building and overseeing our internal financial architecture, and handling and backing the collective input from the investment community. Sara is held in just as high regard inside Insmed as she is beyond it, and we wish her all the best going forward; with that, I'll hand the call to Sara, who will take you through our financial results.

Sara Bonstein

executive
#4

Thank you, Will. I'm happy to walk you through the financial results for the third quarter of 2026 and our updated guidance. In Q3, BRINSUPRI generated $400.1 million in revenue, a 29% increase sequentially off a remarkably strong second quarter. ARIKAYCE brought in $124.4 million of revenue during the quarter, which works out to 9% growth year over year versus the third quarter of 2025. Given how well we've performed so far, we're lifting the bottom end of our revenue guidance for both commercial products. For BRINSUPRI, our full-year revenue guidance of $1.35 billion-$1.4 billion amounts to a $50 million increase to the midpoint of the range we previously provided, and it mirrors the robust execution and results we've achieved to date. For ARIKAYCE, full-year revenue guidance of $460 million-$470 million mirrors the ongoing strength and durability of the franchise, which is now in its ninth year since launch. We still see potential label expansions in the U.S. and Japan during 2027 as a meaningful upside catalyst for ARIKAYCE. Turning to gross to net, we are reiterating our 2026 guidance ranges—mid to high 20s for BRINSUPRI and low to mid-20s for ARIKAYCE. To date, both products have stayed within these ranges. As a reminder, the IRA's small manufacturer provision has enabled us to postpone the effect of covering catastrophic coverage costs for Medicare patients on ARIKAYCE across the last two years, with only a 1% increase each year in 2025 and 2026. Under the small manufacturer phase-in protocol, Insmed's manufacturer coverage cost will rise to 5% in 2027, which will widen ARIKAYCE's gross to net. These phase-in increases will keep occurring annually until Insmed covers the maximum 20% of catastrophic coverage costs in 2031. Now let me move to the other relevant financial metrics for the third quarter. Cost of product revenues came to $78.2 million, or 14.9% of revenues, which on a percentage basis is below the 20.6% recorded in the third quarter of the prior year, reflecting the positive contribution BRINSUPRI makes to the company's gross margin profile. As expected, combined research and development and SG&A expenses rose 40% versus the prior year period, driven by the necessary investments to support the BRINSUPRI launch and to keep funding our pipeline. We continue to manage our investments thoughtfully as BRINSUPRI scales, balancing the opportunity in front of us with disciplined resource allocation. Let me now spend a moment on our cash position and burn rate. At the close of the third quarter, we held approximately $1.1 billion in cash equivalents and marketable securities. Together with BRINSUPRI's continued strong performance, this gives us a clear line of sight toward achieving cash flow positivity in 2027, even as we remain a growth story. Before we open the call to your questions, I want to take a moment to express my deep appreciation for my time at Insmed. When I joined Insmed nearly seven years ago, we were a single-product company with enormous ambition. At this point, we've become a company with multiple products and are on course to reach positive cash flow in the coming year. I depart feeling enormous pride in what we've built as a team and, even more so, in what this organization has done for patients. I'd like to end with two expressions of thanks. To everyone at Insmed: each milestone, each patient we reached, each hurdle we got through together — that is the work that counts, and you are remarkable. To the financial community: your conviction, your capital, and your readiness to put faith in our mission allowed us to unlock this potential. Thanks to your partnership, our financial foundation is stronger than it has ever been. With that, we'd like to open the line now for your questions. Operator, could we please take the first question?

Yesha Patel

analyst
#5

Hello, Yesha here on behalf of Gavin. We realize you aren't giving out specific metrics, but speaking directionally, we were curious whether you could address the way discontinuation trends are developing, particularly as the earlier cohorts age. Are they leveling off with longer-term treatment? And are newer cohorts behaving the same way? Thanks.

Will Lewis

executive
#6

Yes, I appreciate the question. From where I sit, I would say every one of those metrics looks positive. Specifically addressing what you asked, I would say that is exceeding our expectations. Looking ahead, I'm certain questions will arise regarding new patient starts and other items as well. Although we guided that after a year we would cease sharing the specific metrics, let me be very clear that that is positive, and regarding where we head next year, I believe that will keep growing; so on all fronts, I feel quite good about our position, and I would simply point to the things worth watching: TRXs from the Symphony data. October isn't out yet, but it is trending favorably compared with what we observe. Then, when you look at revenue, those are the two items I think matter for a product that is already a blockbuster in its first year of launch.

Yesha Patel

analyst
#7

Thanks a lot, everyone.

Jessica Fye

analyst
#8

Hi, everyone. Morning, and well done on the quarter. Appreciate you taking my questions. Should we anticipate guidance for BRINSUPRI in January, the way you've typically done for ARIKAYCE? And on TPIP, nice work on the enrollment momentum in the ILD trial. What timeline are you thinking about for top-line data on that study and on the PAH trial?

Will Lewis

executive
#9

Yes. I'm jotting things down here; our habit is to give guidance, if we choose to, around the time of your conference, honestly. My expectation is we'd follow that same pattern, looking toward next year for BRINSUPRI, as you're asking. Regarding TPIP, we've said enrollment should finish by the first half of 2028, at the latest, and then the data arrive after whatever period is needed to ensure the database is submission-ready and that sort of thing. Typically that doesn't take very long. Our team is quite adept at turning results around. But after full enrollment happens, then clearly they must run through the duration of the trial, and then we lock the database and analyze the primary endpoint; we'll complete that as fast as we're able. PAH has only just begun; providing guidance on when we believe that will occur is difficult. What I'll be watching there, much as we did in ILD, is how physicians in the market respond to the data we just released. We're hopeful that PAH, given the open label data, will see the enrollment timeline speed up the way ILD did. Of course, PAH is more competitive when it comes to the number of trials underway, but our data are really quite strong, so we're fairly bullish about it. To give a frame of reference relative to expectations, the ILD study is roughly six months ahead of schedule.

Jessica Fye

analyst
#10

All right. Thanks very much.

Faisal Khurshid

analyst
#11

Hi, everyone. Really appreciate you fitting in my question. I realize you're not sharing metrics. What I'd like to ask is whether you can at least describe qualitatively what you're observing and what investors ought to anticipate regarding seasonal patterns for this product. Is there anything significant you can say so far about how the summer played out versus what you're seeing now in the fall, for instance, and how that is shaping your view of the fourth quarter? Thanks.

Will Lewis

executive
#12

Yes. A lot of discussion has centered on August and what the Symphony data showed. My take is that Symphony data is fairly accurate, though not in every case. All I'd say is that it's too soon for us to comment on seasonality. Honestly, I don't view it as a major factor. We didn't really observe it to any substantial degree in the clinical trial setting; we'll have far more clarity once this cold and flu season gets underway and we see what comes of it. Do I believe there's a theoretical possibility that it could heighten awareness of exacerbations and bring people in to see their pulmonologist? Yes, I do. Considering that might occur isn't unreasonable, in my view. I can't say how it will unfold in Q4 or in the early portion of next year, but I wouldn't build much seasonality into your models until we're able to say something more definitive. My guess is that won't happen until roughly spring of next year, when we can look back over the whole of this period and speak to what we've observed. The trends within the launch are extremely strong. I want to be absolutely clear on that point. As I've mentioned, with the metrics we gave, new patient starts, I believe you'll see growth there through next year. I think you're also going to see the other metrics we've discussed previously, such as persistency, and they are far ahead of benchmarks, so we feel terrific about how this launch is shaping up. If there's one insight I could offer, I'd say the most powerful force driving this launch is probably persistency. Many of the patients who start this drug feel better, and they remain on it. You can see that reflected in a great deal of the public commentary from patients. Things are going very, very well.

Faisal Khurshid

analyst
#13

That's great. Thanks, Will, and it's good to get a bit of an upside surprise on Symphony, so I do appreciate the progress you folks are making.

Will Lewis

executive
#14

Thanks.

Andrea Newkirk

analyst
#15

Morning, and thanks for taking my question. To start, Sara, I simply want to express my appreciation for your partnership and offer my best wishes for success in your upcoming leadership position. Will, when you consider future growth for BRINSUPRI, what are you observing regarding how prescriber breadth is evolving compared with depth? What share would you estimate presently comes from beyond those specialists and into the wider community pulmonology setting? If I may slip in a brief question for Sara regarding the route to positive cash flow: could you assist us in thinking through how to model expenses across roughly the coming year as the TPIP studies get going, and what level of quarterly product revenue from BRINSUPRI and ARIKAYCE do you expect would be needed to reach operating cash flow breakeven? Many thanks.

Will Lewis

executive
#16

Regarding the breadth and depth of doctors, what I'd say is that clearly we're aiming for both, though there's a specific focus on depth among the physicians already prescribing. I'd also draw a line between certain centers of excellence and those physicians who operate in strong settings yet aren't viewed as, say, National Jewish is when it comes to how prominent their practice is. At institutions such as National Jewish, nearly every patient who arrives with BE is being given BRINSUPRI. What constrains them there is getting patients on the schedule. As an illustration, the amount we've been able to produce from that site has been excellent. Several others fit that same pattern too. The chance we have here in terms of both scope and depth—depth meaning the kinds of organizations supporting those centers of excellence, which serve large patient populations and have reached a point where we can honestly state that literally tens of thousands of patients have received this medicine. Its adverse event profile is remarkably benign. Accounts of patients feeling better, though we can't go into detail on that, are now everywhere. As a result, this medicine enjoys a very favorable reputation within the treating community. Samuele Butera, our new therapeutic area head for respiratory, has I believe made a key contribution by steering a far more targeted outreach toward particular pulmonology practices and, more broadly, by making our conversations about how this drug helps patients more direct, in a way that is both appropriate and compliant. To put it another way, we now have plenty of evidence showing that patients who start on this drug will benefit outside of the clinical trial context. The real-world evidence supporting this drug is very strong, and that is a message we need to bring straight to physicians. Let's begin with depth across many of the larger practices sitting beneath the centers of excellence, which are already close to full capacity, and after that there's room for breadth too. I'll now hand things to Sara, who will cover the cash flow picture.

Sara Bonstein

executive
#17

Appreciate the question, Andrea, and thanks for the kind remarks. It's always good to talk with you. A few points regarding costs. I clearly won't give out specific quarterly revenue figures, but here's what I can tell you: the ratio of revenue to SG&A that we keep observing can keep getting better, and we expect improved and rising margins in that area. The BRINSUPRI revenue is on a strong path — as Will mentioned in the prepared remarks and as I've said too — it's already a blockbuster and keeps holding that status, and we expect that growth to carry on in the years ahead. On TPIP expenses specifically, what you saw in this year's financials is that there were actually some meaningful TPIP costs. If you look through the MD&A section in the Q, you'll find we had to put money into manufacturing to prepare for those four phase III trials. That investment is behind us now, and it will shift over to clinical trial spending. Given the direction of our revenue, we're quite confident about being cash flow positive next year, and we'll invest as the science guides us to.

Ritu Baral

analyst
#18

Morning, everyone, and nice work on the results this quarter for BRINSUPRI. I had a question about the comorbid population. Will, you said campaigns are going to be underway, and you cited some large figures, I believe 200. And the numbers on comorbid look pretty big; they don't appear to line up with what at least our KOLs think about the undiagnosed and misdiagnosed comorbid population. Could you get into the details on awareness? And do you still believe that this will begin to serve as a tailwind for BRINSUPRI in 2027? Thank you.

Will Lewis

executive
#19

Yes. Let me just clarify — when you say it doesn't comport with what you've heard from KOLs, what's the frame of reference there? Is there something specific I can respond to?

Ritu Baral

analyst
#20

Sure. They just aren't convinced that there are very many people who have both conditions or are undiagnosed — at least when it comes to bronchiectasis — who would be worth treating. So how do we plan to build awareness around those figures?

Will Lewis

executive
#21

Yeah. I'd start with what's already been published by the medical community; the range is broad, so to keep things conservative we can focus on the low end. But the literature as it currently stands shows that somewhere between 4% and 64% of COPD patients — this is in published literature — also have bronchiectasis. At the bottom of that range, that comes to 800,000 patients; so a larger number than those currently diagnosed. Our own estimate is actually larger. The key opinion leaders we've consulted — who may not be the same people you're talking to — including physicians at COPD and asthma centers of excellence, cite a figure around 20%, and that's the basis for our single-digit millions estimate. Greater precision should come within roughly the next year, as we conduct extensive additional work with centers of excellence, reviewing prior CT scans retrospectively and identifying signs of bronchiectasis, among other efforts. We consistently hear that comorbidity is substantial. So I'd like to understand the source of that perspective. I'm certain there are people with differing views, but the evidence that these patients exist in large numbers seems quite compelling to me. We held a gathering in Germany—and I'll have Martina share her perspective on how it went shortly—where we invited specialists from the COPD and asthma fields to the World Bronchiectasis Conference, and they made the trip specifically to address this topic. The strongest proof we can point to that this problem is genuine—and widespread—is that the GOLD guidelines for COPD have already been updated. They now state that when a patient is receiving maximum-dose therapy yet continues to experience exacerbations, a high-resolution CT scan should be performed to check for bronchiectasis, and if that condition is found, the patient should be started on BRINSUPRI. Martina, would you like to add anything?

Martina Flammer

executive
#22

Yes. And Ritu, perhaps this also speaks to how crucial it is that the physician and expert communities now collaborate and examine their patient populations to determine what may be driving the disease — and if patients keep exacerbating, is the underlying cause COPD or is it genuinely bronchiectasis? That significance of investigating what drives it, and even posing that question, is precisely where COPD and BE specialists are joining forces. This isn't happening only in Germany. It was the World Bronchiectasis Conference where the first of those meetings was held. A second meeting has now also taken place at CHEST. That, I think, is where we're seeing the international community of those experts come together. Keep in mind, back when there was no treatment for bronchiectasis, it wasn't top of mind for the pulmonary community; now there is, and we've witnessed this with other disease areas; it invites a different way of thinking about what is driving my patient. You need to ask whether my patient is optimally treated for COPD but still exacerbates — what is driving that? Then, as a second question, you have to consider, is there a diagnosis I might have missed, or perhaps I did see it but haven't acted on it? That's what the COPD and BE community is discussing right now. I believe we can expect that they will, in due course, also take a stance on this. But we're still at the early stages, though it's well recognized by the expert community, and soon it will be by the broader pulmonary community.

Will Lewis

executive
#23

I'd like to add one more point to that. When we discuss COPD and asthma occurring alongside bronchiectasis, we are actively searching for bronchiectasis within those groups of patients. So there's no extra clinical trial effort required on our part to treat these individuals. As soon as someone receives a bronchiectasis diagnosis, they become eligible and are on-label for BRINSUPRI. That's different from the COPD patients we're going after with 1033. If the phase I study next year turns out the way we anticipate, we'll initiate a phase II trial in COPD patients. Martina, would you like to say a bit about what those patients look like and how they differ from those who have bronchiectasis as a comorbidity?

Martina Flammer

executive
#24

Right. When we consider the COPD population, neutrophils act as the inflammatory driver in most cases of COPD. They play a primary role there in COPD. What we're aiming for with 1033 as a novel DPP1 is to tackle the disease drivers and the inflammation in COPD patients. It isn't the bronchiectasis element. It's COPD as a disease whose driver is neutrophils. That will be the focus and the indication we're pursuing with 1033. The reason we sense a strong component of that is the overlap among those kinds of disease pathophysiologies. With 1033 having already been well-characterized from a mechanistic standpoint, and with a solid understanding of what BRINSUPRI does, we've known what the profiles are; that gives us, I think, a better insight already into how the development program will go, and this will be the focus, as Will mentioned, on COPD as a standalone disease.

Ritu Baral

analyst
#25

Great. Thank you.

Jason Zemansky

analyst
#26

Good morning. Congratulations on the tremendous progress, and thank you for taking our question. Will, perhaps to tie a few things together, we were hoping to understand how patient mix is changing now that you're basically a year into the launch. Are you seeing new starts coming from diagnosed high exacerbators who are waiting, or has there been a move toward those less severe patients in earlier lines of use? What does that suggest about how much demand remains untreated, particularly as you go deeper with existing prescribers? Thanks.

Will Lewis

executive
#27

Yeah. I think there's another growth phase ahead for this drug in this indication. Physicians typically start a new medicine—especially one with a novel mechanism—by treating their most severe patients, and once that experience proves so positive, they shift toward patients who are perhaps less severe, more moderate. That group represents a substantial share of the market opportunity. Building that sense of urgency to treat—rather than waiting for an exacerbation to cause the permanent damage it will cause—is an important part of what the therapeutic specialists discuss with physicians, to make sure they see, hey, look, this medicine is working. Frequently, patients experience improvement while taking it, and because of that, you ought to be considering it for larger groups of people. Once that shift gains momentum, my expectation is that it will turn into the standard treatment for this condition—rather than a situation where someone arrives, shows a particular set of characteristics, and the doctor then makes a deliberate decision to prescribe it. My guess is this will turn into a really fundamental piece of care for essentially every bronchiectasis patient. One doctor put it to me this way — and I keep repeating his line — while I was attending one of those conferences, he clapped me on the shoulder and asked, "How does it feel to have a statin for the lungs?" That, I believe, is the direction we're headed.

Jason Zemansky

analyst
#28

Thanks for the background.

Joseph Schwartz

analyst
#29

Hi there, and thank you. Will, along with the team, congratulations on a strong set of results. Sara, I appreciate the excellent financial leadership. On the branded marketing for BRINSUPRI, what increase in new patient starts do you expect, and how soon would that response appear? What kind of return would have to be demonstrated before you materially scale that spending? And in what way do you measure whether that initiative is succeeding? Thank you.

Will Lewis

executive
#30

Yes. Advertising aimed directly at consumers generally does work. In my view it becomes especially effective once the groundwork is in place, when the physician community already holds a very positive perception of the medicine, and when a solid record of success already exists. My sense is this raises our odds of achieving an even stronger return. Ordinarily, an AI search would show you a return on capital of roughly 2x to 3x. My guess is that in this instance it may come in above that level, though time will tell. We will definitely be monitoring it closely. Am I expecting demand to go up? Yes, I am. That should start becoming visible, most likely, during the first half of next year. We'll be following it quite closely, and let me be clear: we aren't taking budget away from one advertising area and shifting it into DTC. It's incremental. And it also won't consist solely of TV ads. We're running digital campaigns as well, plus other methods to reach patients and physicians appropriately. What you'll likely see is a broader effort on all fronts, and that should certainly work to the brand's advantage.

Maxwell Skor

analyst
#31

Great. Thanks so much for taking my question. Just building on the comorbid COPD and asthma opportunity. Finding these patients appears to be one part of the puzzle. Perhaps you could say a bit more about how AI is helping with that effort. Conversely, what needs to change, or do you foresee any challenges when it comes to reimbursement? And lastly, could you potentially narrow down when we might expect greater visibility into this opportunity? Thank you very much.

Will Lewis

executive
#32

Sure. The comorbid opportunity, I'm glad it's getting a lot of attention. In my view, this is unquestionably the largest opportunity currently at Insmed, with TPIP close behind—assuming phase III delivers as phase II did, given what that prospect could mean; those two things will fuel this company's growth over the coming ten years. On finding these patients, yes, we're using AI tools in an effort to do so. It's a multi-layered approach; we're approaching certain equipment makers directly to explore whether it can be built into their software. We are in conversations with hospitals that establish their own protocols for when a patient arrives and receives a high-resolution CT scan, with the aim of boosting the likelihood that such a scan could be treated as a default examination. As things stand, a radiologist who isn't specifically instructed to check for bronchiectasis might fail to spot it even when present. Given that a treatment for this condition now exists, revising that protocol is entirely logical for a hospital; in all probability it will enhance their outcome performance scores. So the advantages are substantial and momentum is strong, yet this is an oil tanker—turning it will require some time. You're asking how that eventually gets patients entering at the top of the funnel, so to speak. I think we'll start to see that in 2027, and definitely in 2028 and after; but this is a huge potential opportunity, and we plan to put substantial resources behind it. Do I believe it will alter reimbursement? We haven't observed that so far. We don't anticipate that will happen. The fact is, all of these patients are on label. There's no one who is a non-bronchiectatic patient when it comes to a definitive diagnosis. And the key point is that, for those patients coming through at this moment—including with insurers that don't actually have an arrangement in place with us, where we're pursuing a medical exception—our approval rates remain extraordinarily high. So regardless of whether it goes through the medical exception route or through the requirements set out in the agreements we've already finalized, patients are being approved, and physicians out there understand this. I don't see that becoming a source of friction. If it were to expand to the point where friction did develop, I think everyone would welcome that scenario—and above all, it would be good for the patients. On the question of when we'll begin to see it, as I mentioned, around the middle of next year we should start being able to put numbers on this with more precision, which I think will help since the range is quite wide at the moment. However you look at it, we believe this is a very substantial population—one that justifies a dedicated task force inside the company giving it full attention, and that's how it's staffed. So hopefully that—

Maxwell Skor

analyst
#33

Excellent. Many thanks.

Will Lewis

executive
#34

provides a bit of background for you.

Maxwell Skor

analyst
#35

Yes. Well done again on this quarter. Many thanks.

Leonid Timashev

analyst
#36

Hi, appreciate you fielding my question. I'd like to hear about those longer-term studies you have underway, including a few of the strategic collaborations, and in particular the BEST-BE study, I suppose. What do you anticipate there? Do you generally expect the exacerbation rate to look like what the clinical trials showed? Or given that the patient population could differ, might the rate come out differently? What I'm really driving at is whether there's any risk that patients not doing as well could shape how physicians perceive the drug. And finally, could this be something you're able to secure on label or get into a publication that you can detail around? Thanks.

Will Lewis

executive
#37

Absolutely, we anticipate that every piece of data emerging from these studies will be disseminated and appear in publications, and that is always beneficial for a brand or a medicine. I believe long-term evidence will prove especially important as we enter a competitive landscape where another company's DPP1, we assume, gains approval. We want to ensure we can clearly communicate the long-term benefit, including potentially modifying the disease, which is part of the intent behind the study in Europe. A great deal will be gleaned from this. I wouldn't expect performance to differ unless an over-enrolled cohort happens to consist of Asian patients, in whom we'd anticipate efficacy exceeding threefold; that's simply an odd result of this drug across those populations, something we and others have now thoroughly documented. So that's a key distinction, especially when considering the makeup of rival DPP1 trials being conducted. Among Japanese patients, we see a 68% decrease in exacerbations. No matter what other data gets presented, my focus would be on comparing that drop in exacerbations with what was seen in their Asian population, and then running a distinct evaluation for the remaining patients, since the impact varies substantially from person to person. The purpose of these extended trials is to uncover some of those factors and to assess the advantages across many years in a sizable patient group, and in my view the outcome will be entirely favorable.

Olivia Brayer

analyst
#38

Hi, good morning, and thanks for the question. I'd also like to quickly thank Sara for everything she's done and contributed throughout the year. On brensocatib, with the launch going as strongly as it has, has your thinking shifted at all regarding the addressable patient population? Is 250,000 still the figure we should be using, or are you beginning to see that opportunity widen — perhaps even because brensocatib is driving awareness and diagnosis now that it's on the market? I also wanted to ask a follow-up on TPIP. Will, you said earlier that enrollment in the ILD study is running ahead of expectations. Could you help us understand how the monthly enrollment rate has shifted now that so many additional sites are up and running? Thanks so much.

Will Lewis

executive
#39

Absolutely. Regarding brensocatib, the market we can address is definitely getting larger. The last time we provided guidance, the total was roughly 500,000 or 550,000 patients in the U.S. diagnosed with non-cystic fibrosis bronchiectasis. That number was derived from claims data, which made it fairly precise. That was three years back. So we certainly think it has increased since that time. What is behind that increase? One factor is simply growth in the population. The second factor is obviously that when a medicine arrives, it invariably draws patients out who had been hidden until then, since previously there was nothing available to treat them. That is what we observed with ARIKAYCE too, and that launch proved very strong as a result of the patient-finding effort and the awareness that these patients at last had a medicine available. Then the third growth driver is plainly patients who in the past were less severe but now have greater awareness of the exacerbations they are experiencing. They are reporting those exacerbations better than before. There is more awareness of exacerbations, and people are on the lookout for them. Patients are being asked about these treatments by their doctors and at clinics, and that is likely to move some people who were classified as mild to moderate—meaning fewer than two exacerbations annually—into a higher category. As a result, the number of patients with two or more exacerbations will grow, and that group is precisely where the bulk of our efforts have been directed. Keep in mind that the label permits any patient with non-cystic fibrosis bronchiectasis to use the medicine. Our emphasis on the moderate to severe segment came from what we heard in discussions with KOLs. We believe those individuals stand to gain the most right away. In my view, this does eventually reach wider patient populations. Assuming all of that happens, I'd anticipate this patient group will keep expanding at a solid pace — and that's separate from the COPD and BE comorbid patients we mentioned earlier. Regarding your TPIP question, I think you were asking about how enrollment trends month to month; we won’t break it down to that degree of detail, but I’d simply note that over time — and we observed this with our phase II efforts — fresh data coming in on TPIP plainly serves as a trigger for an increased pace of enrollment as well as response; this summer, when the open label data in PAH came out, it generated a marked uptick in interest and in the willingness to sign up patients in both ILD and PAH. So that’s encouraging for us. I believe this drug's once-a-day dosing with essentially a single inhalation is a real advantage, and so is its ability to deliver larger quantities of the medicine so you can titrate up to the patient's maximum tolerated dose, reaching as high as 1,280 — a very meaningful increase over what's available today. It's convenient, it's more medicine, it's better side effects. What we've seen with this so far has been nothing short of stunning, and I think that will continue. As evidence of that circulates and physicians grow more aware, it certainly speeds up their desire to get patients on the trial.

Operator

operator
#40

That brings us to the end of the question-and-answer portion, and today's call is now finished. We appreciate everyone joining us. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Insmed Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Insmed Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Insmed Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.